Luke Sergott
Stock Analyst at Barclays
(3.18)
# 1,098
Out of 5,147 analysts
383
Total ratings
45.96%
Success rate
1.29%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $15 → $12 | $10.72 | +11.94% | 15 | Feb 27, 2026 | |
| CERT Certara | Maintains: Overweight | $13 → $8 | $7.08 | +12.99% | 21 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $150 | $121.38 | +23.58% | 15 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $200 → $175 | $128.73 | +35.94% | 5 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $215 → $200 | $178.49 | +12.05% | 12 | Feb 19, 2026 | |
| WST West Pharmaceutical Services | Maintains: Equal-Weight | $325 → $265 | $254.34 | +4.19% | 5 | Feb 13, 2026 | |
| BRKR Bruker | Maintains: Overweight | $55 → $50 | $40.11 | +24.66% | 9 | Feb 13, 2026 | |
| AVTR Avantor | Maintains: Equal-Weight | $12 → $9 | $9.05 | -0.55% | 28 | Feb 12, 2026 | |
| MEDP Medpace Holdings | Maintains: Underweight | $525 → $500 | $451.76 | +10.68% | 6 | Feb 11, 2026 | |
| WAT Waters | Reinstates: Overweight | $400 | $319.38 | +25.24% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $210 | $178.81 | +17.44% | 25 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $50 | $46.92 | +6.56% | 21 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $98.31 | +20.03% | 13 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $625 → $650 | $521.11 | +24.73% | 30 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $52 | $49.80 | +5.18% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $2 | $1.68 | +19.05% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $208.04 | +29.78% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,600 → $1,550 | $1,366.69 | +13.41% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $134.46 | -18.19% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $185 → $200 | $108.14 | +84.95% | 23 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $93.90 | +27.80% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $23.05 | -4.56% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $103.38 | +1.57% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $16.25 | +23.08% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $210.64 | +18.69% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $101.27 | -11.13% | 1 | Aug 1, 2025 |
Fortrea Holdings
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $10.72
Upside: +11.94%
Certara
Feb 27, 2026
Maintains: Overweight
Price Target: $13 → $8
Current: $7.08
Upside: +12.99%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $165 → $150
Current: $121.38
Upside: +23.58%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $200 → $175
Current: $128.73
Upside: +35.94%
Charles River Laboratories International
Feb 19, 2026
Maintains: Overweight
Price Target: $215 → $200
Current: $178.49
Upside: +12.05%
West Pharmaceutical Services
Feb 13, 2026
Maintains: Equal-Weight
Price Target: $325 → $265
Current: $254.34
Upside: +4.19%
Bruker
Feb 13, 2026
Maintains: Overweight
Price Target: $55 → $50
Current: $40.11
Upside: +24.66%
Avantor
Feb 12, 2026
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $9.05
Upside: -0.55%
Medpace Holdings
Feb 11, 2026
Maintains: Underweight
Price Target: $525 → $500
Current: $451.76
Upside: +10.68%
Waters
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $319.38
Upside: +25.24%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $230 → $210
Current: $178.81
Upside: +17.44%
Feb 3, 2026
Maintains: Overweight
Price Target: $39 → $50
Current: $46.92
Upside: +6.56%
Feb 3, 2026
Maintains: Overweight
Price Target: $115 → $118
Current: $98.31
Upside: +20.03%
Jan 30, 2026
Maintains: Overweight
Price Target: $625 → $650
Current: $521.11
Upside: +24.73%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $49.80
Upside: +5.18%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $2
Current: $1.68
Upside: +19.05%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $208.04
Upside: +29.78%
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,366.69
Upside: +13.41%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $134.46
Upside: -18.19%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $108.14
Upside: +84.95%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $93.90
Upside: +27.80%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $23.05
Upside: -4.56%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $103.38
Upside: +1.57%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $16.25
Upside: +23.08%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $210.64
Upside: +18.69%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $101.27
Upside: -11.13%